These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 4138271)

  • 1. Letter: Basic encephalitogen and unresponsive multiple sclerosis.
    Horan AH
    Lancet; 1974 Oct; 2(7886):962. PubMed ID: 4138271
    [No Abstract]   [Full Text] [Related]  

  • 2. Lymphocytes sensitised to basic encephalitogen in patients with multiple sclerosis unresponsive to steroid therapy.
    Webb C; Teitelbaum D; Abramsky O; Arnon R; Sela M
    Lancet; 1974 Jul; 2(7872):66-9. PubMed ID: 4137047
    [No Abstract]   [Full Text] [Related]  

  • 3. Cellular hypersensitivity in attacks of multiple sclerosis. I. A comparative study of migration inhibitory factor production and lymphoblastic transformation in response to myelin basic protein in multiple sclerosis.
    Colby SP; Sheremata W; Bain B; Eylar EH
    Neurology; 1977 Feb; 27(2):132-9. PubMed ID: 556829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and immunologic studies on multiple sclerosis.
    Tsubaki T; Horikawa Y; Iwata I; Amaya N
    Neurology; 1976 Jun; 26(6 PT 2):35-6. PubMed ID: 58394
    [No Abstract]   [Full Text] [Related]  

  • 5. [Myelin basic protein stimulation index of CD 2 cells in the course of steroid treatment].
    Wender M; Sniatała-Kamasa M; Wójcicka M; Tokarz-Kupczyk E; Losy J
    Neurol Neurochir Pol; 1999; 33(4):765-70. PubMed ID: 10612091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphocyte sensitization to basic protein of brain in multiple sclerosis and other neurological diseases.
    Caspary EA; Field EJ
    J Neurol Neurosurg Psychiatry; 1974 Jun; 37(6):701-3. PubMed ID: 4135820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct leukocyte migration inhibition by myelin basic protein in exacerbations of multiple sclerosis.
    Sheremata W; Triller H; Cosgrove JB; Eylar EH
    Can Med Assoc J; 1977 May; 116(9):985-8. PubMed ID: 870161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunopathogenesis of multiple sclerosis: MBP and beyond.
    Meinl E; Hohlfeld R
    Clin Exp Immunol; 2002 Jun; 128(3):395-7. PubMed ID: 12067291
    [No Abstract]   [Full Text] [Related]  

  • 9. [Administration of encephalitogenic basic protein in the diagnosis of multiple sclerosis and Guillain-Barré syndrome].
    Wajgt A; Wiktorowicz K; Torliński L
    Neurol Neurochir Pol; 1974; 8(5):653-62. PubMed ID: 4139672
    [No Abstract]   [Full Text] [Related]  

  • 10. Antimyelin basic protein antibodies and cellular hypersensitivity in multiple sclerosis.
    Sheremata W; Wood DD; Moscarello MA
    Trans Am Neurol Assoc; 1976; 101():291-4. PubMed ID: 1028264
    [No Abstract]   [Full Text] [Related]  

  • 11. The T-lymphocyte response against myelin-associated glycoprotein and myelin basic protein in patients with multiple sclerosis.
    Zhang Y; Burger D; Saruhan G; Jeannet M; Steck AJ
    Neurology; 1993 Feb; 43(2):403-7. PubMed ID: 7679782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endogenous interferon-β-inducible gene expression and interferon-β-treatment are associated with reduced T cell responses to myelin basic protein in multiple sclerosis.
    Börnsen L; Romme Christensen J; Ratzer R; Hedegaard C; Søndergaard HB; Krakauer M; Hesse D; Nielsen CH; Sorensen PS; Sellebjerg F
    PLoS One; 2015; 10(3):e0118830. PubMed ID: 25738751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Where to hit MS.
    Lancet; 1991 Mar; 337(8744):765-7. PubMed ID: 1706449
    [No Abstract]   [Full Text] [Related]  

  • 14. MS and EAE.
    Lancet; 1979 Nov; 2(8150):1001-2. PubMed ID: 91724
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunochemistry and biochemistry of myelin.
    Davison AN; Cuzner ML
    Br Med Bull; 1977 Jan; 33(1):60-6. PubMed ID: 64271
    [No Abstract]   [Full Text] [Related]  

  • 16. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis.
    Ota K; Matsui M; Milford EL; Mackin GA; Weiner HL; Hafler DA
    Nature; 1990 Jul; 346(6280):183-7. PubMed ID: 1694970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The short-term effect of an immunosuppressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis.
    Lamers KJ; Uitdehaag BM; Hommes OR; Doesburg W; Wevers RA; von Geel WJ
    J Neurol Neurosurg Psychiatry; 1988 Oct; 51(10):1334-7. PubMed ID: 2465387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delayed dermal hypersensitivity to autologous lymphocytes in multiple sclerosis.
    Morariu M; Böhm T
    Neurology; 1973 Aug; 23(8):808-11. PubMed ID: 4352601
    [No Abstract]   [Full Text] [Related]  

  • 19. Letter: Linoleic acid in multiple sclerosis.
    Paty DW; Cousin HK; McDonald LE
    Lancet; 1975 May; 1(7917):1197-8. PubMed ID: 48822
    [No Abstract]   [Full Text] [Related]  

  • 20. Cell-mediated immunity to myelin basic protein in acute disseminated encephalomyelitis.
    Lisak RP; Behan PO; Zweiman B; Shetty T
    Neurology; 1974 Jun; 24(6):560-4. PubMed ID: 4133960
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.